Baricitinib + TNF Inhibitor
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Feb 14, 2020 → May 19, 2025
NCT ID
NCT04086745About Baricitinib + TNF Inhibitor
Baricitinib + TNF Inhibitor is a approved stage product being developed by Eli Lilly for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04086745. Target conditions include Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04086745 | Approved | Completed |
| NCT03915964 | Approved | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| CT-P17 SC AI (adalimumab) | Celltrion | Phase 3 | 77 |
| Remsima IV + Remsima SC | Celltrion | Pre-clinical | 23 |
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P47 + EU-approved RoActemra | Celltrion | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 3 | 77 |
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Rituximab, MTX, folic acid | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan + MabThera | Celltrion | Phase 3 | 77 |
| CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 3 | 77 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P17 SC + Humira SC | Celltrion | Phase 3 | 77 |
| Adalimumab | Celltrion | Pre-clinical | 23 |
| Infliximab | Celltrion | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Pre-clinical | 23 |